According to Zhitong Finance App, Dongyang Pharmaceutical (06887.HK) issued an announcement. On September 23, 2026, the Company submitted a filing application (application) to the China Securities Regulatory Commission for the conversion of 389.217 million domestic shares of the Company's shareholders to the Company's H shares, accounting for about 6.75% of the total issued share capital of the Company on the date of this announcement (full circulation of H shares).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.